Phase 2 Hypertension Trial, Recruiting NCT05924971 Sponsor: MemorialCare Health System Condition: Hypertension
Back to Hypertension

Phase 2 Hypertension Trial, Recruiting

NCT05924971
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with a serious form of high blood pressure during pregnancy (called preeclampsia with severe features) that was identified during their delivery hospital stay.
  • People whose pregnancy care (both before and after birth) was provided by the Long Beach Memorial Ob/Gyn resident team or the Maternal-Fetal Medicine clinic.

Who may not be able to join:

  • People under 18 years of age.
  • People who do not speak English or Spanish.
  • People who were diagnosed with high blood pressure before 20 weeks of pregnancy (meaning the high blood pressure existed before the pregnancy-related condition developed).
  • People with a known allergy to aspirin, a previous bad reaction to aspirin, or certain health conditions where aspirin is considered unsafe — such as nasal polyps, stomach or small intestine ulcers, a history of gastrointestinal bleeding, or serious liver problems.
  • People who have already been prescribed aspirin after giving birth for a different medical reason.
  • People with a bleeding disorder.
  • People who are breastfeeding a baby with a low platelet count (a blood condition that can affect clotting).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Megan C Oakes, MD MSCI, Miller Children's and Women's Hospital, Long Beach/ MemorialCare Medical Center

Phone: 562-997-8510

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
MemorialCare Health System
Registry
ClinicalTrials.gov
Start date
26 July 2023
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Reduction in sFlt-1

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov